Sunlenca 464 mg solution for injection
*Company:
Gilead Sciences LtdStatus:
UpdatedLegal Category:
Product subject to medical prescription which may not be renewed (A)Active Ingredient(s):
This medicinal product is subject to additional monitoring.
*Additional information is available within the SPC or upon request to the company
Updated on 05 March 2025
File name
Sunlenca Injection Ireland SmPC (January 2025).pdf
Reasons for updating
- Change to section 4.2 - Posology and method of administration
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 4.8 - Undesirable effects
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may not be renewed (A)
Updated on 05 March 2025
File name
Sunlenca Injection Ireland PIL (January 2025).pdf
Reasons for updating
- Change to section 4 - possible side effects
- Change to section 6 - date of revision
- Change to section 7 - Instructions for use
Updated on 22 October 2024
File name
Sunlenca Injection IE-XI SmPC (Sept 2024).pdf
Reasons for updating
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 5.2 - Pharmacokinetic properties
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may not be renewed (A)
Updated on 28 August 2024
File name
Sunlenca Injection IE-XI PIL (July 2024).pdf
Reasons for updating
- Correction of spelling/typing errors
Updated on 28 August 2024
File name
Sunlenca Injection IE-XI SmPC (July 2024).pdf
Reasons for updating
- Change to section 5.3 - Preclinical safety data
Legal category:Product subject to medical prescription which may not be renewed (A)
Updated on 30 June 2023
File name
Sunlenca - Injection - IE-XI PIL (June 2023).pdf
Reasons for updating
- Change to section 2 - pregnancy, breast feeding and fertility
Updated on 30 June 2023
File name
Sunlenca - Injection - IE-XI SmPC (June 2023).pdf
Reasons for updating
- Change to section 4.6 - Pregnancy and lactation
- Change to section 6.3 - Shelf life
Legal category:Product subject to medical prescription which may not be renewed (A)
Updated on 21 October 2022
File name
Sunlenca - Injection - IE-XI SmPC (August 2022) - updated.pdf
Reasons for updating
- New SPC for new product
Legal category:Product subject to medical prescription which may not be renewed (A)
Updated on 21 October 2022
File name
Sunlenca - Injection - IE-XI PIL (August 2022) - updated.pdf
Reasons for updating
- New PIL for new product
Gilead Sciences Ltd
Address:
280 High Holborn, London, WC1V 7EE, UKMedical Information E-mail:
ukmed.info@gilead.comTelephone:
+44 (0)203 681 4500Medical Information Direct Line:
+353 214 825 999 , 08000 113 700 (UK)Customer Care direct line:
+44 (0)203 681 4681